Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomericaBMRA -6.28%50 Gross Margin % is -4.46% as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Biomerica ranks worse than 95.65% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Biomerica's Gross Profit for the
three
months ended in Feb. 2026 was $-0.04 Mil. Biomerica's Revenue for the
three
months ended in Feb. 2026 was $0.99 Mil. Therefore, Biomerica's Gross Margin % for the quarter that ended in Feb. 2026 was -4.46%.
Warning Sign:
Biomerica Inc gross margin has been in long-term decline. The average rate of decline per year is -9.1%.
The historical rank and industry rank for Biomerica's Gross Margin % or its related term are showing as below:
BMRA'
s Gross Margin % Range Over the Past 10 Years
Min: 4.32 Med: 20.31 Max: 34.91
Current: 4.32
During the past 13 years, the highestGross Margin % of Biomerica was 34.91%. The lowest was 4.32%. And the median was 20.31%.
BMRA's Gross Margin % is ranked worse than 95.65% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs BMRA: 4.32
Biomerica had a gross margin of -4.46% for the quarter that ended in Feb. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Biomerica was -9.10% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biomerica had a gross margin of -4.46% for the quarter that ended in Feb. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biomerica Gross Margin % Related Terms
Biomerica Gross Margin % Historical Data
* Premium members only.
The historical data trend for Biomerica's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMRA vs WOK, ALURD, ITOC: Gross Margin % Comparison
For the Medical Devices subindustry, Biomerica's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomerica Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Biomerica's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biomerica (BMRA) has a Gross Margin % of -4.46% as of Feb. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Biomerica and its competitors. Over the past decade, Biomerica's Gross Margin % has ranged from 4.32 to 34.91. According to the industry distribution chart, Biomerica ranks #770 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is Biomerica's Gross Margin % too high?
Biomerica's current Gross Margin % is -4.46%. Over the past 10 years, this metric has ranged from a low of 4.32 to a high of 34.91. Based on the distribution chart, Biomerica ranks #770 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Gross Margin % compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #770 out of 805 companies for Gross Margin %. This places Biomerica in the lower half of its industry. The industry median Gross Margin % is 52.07. Historically, Biomerica's own Gross Margin % has ranged from 4.32 to 34.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Biomerica and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomerica's current Gross Margin % is -4.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Gross Margin % is -4.46%. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Biomerica (BMRA), the current Gross Margin % is -4.46% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomerica (BMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Biomerica stock appears to be undervalued.
The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18.
GuruFocus considers Biomerica to be Possible Value Trap.
Key valuation signals for BMRA:
Gross Margin %: -4.46%
GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score
Get the complete analysis for BMRA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRA has been successfully added to your 
